Novel bispecific PSMA/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer

A new series of bispecific radioligands (BRLs) targeting prostate-specific membrane antigen (PSMA) and gastrin releasing peptide receptor (GRPr), both expressed on prostate cancer cells, was developed. Their design was based on the bombesin (BN) analogue, H2N-PEG2-[d-Tyr6,β-Ala11,Thi13,Nle14]BN(6-14...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Liolios, Christos (VerfasserIn) , Schäfer, Martin (VerfasserIn) , Haberkorn, Uwe (VerfasserIn) , Eder, Matthias (VerfasserIn) , Kopka, Klaus (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: January 4, 2016
In: Bioconjugate chemistry
Year: 2016, Jahrgang: 27, Heft: 3, Pages: 737-751
ISSN:1520-4812
DOI:10.1021/acs.bioconjchem.5b00687
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1021/acs.bioconjchem.5b00687
Volltext
Verfasserangaben:C. Liolios, M. Schäfer, U. Haberkorn, M. Eder, and K. Kopka

MARC

LEADER 00000caa a2200000 c 4500
001 1699161631
003 DE-627
005 20230427032015.0
007 cr uuu---uuuuu
008 200602s2016 xx |||||o 00| ||eng c
024 7 |a 10.1021/acs.bioconjchem.5b00687  |2 doi 
035 |a (DE-627)1699161631 
035 |a (DE-599)KXP1699161631 
035 |a (OCoLC)1341327277 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Liolios, Christos  |e VerfasserIn  |0 (DE-588)1205337059  |0 (DE-627)1690922826  |4 aut 
245 1 0 |a Novel bispecific PSMA/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer  |c C. Liolios, M. Schäfer, U. Haberkorn, M. Eder, and K. Kopka 
264 1 |c January 4, 2016 
300 |a 15 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 02.06.2020 
520 |a A new series of bispecific radioligands (BRLs) targeting prostate-specific membrane antigen (PSMA) and gastrin releasing peptide receptor (GRPr), both expressed on prostate cancer cells, was developed. Their design was based on the bombesin (BN) analogue, H2N-PEG2-[d-Tyr6,β-Ala11,Thi13,Nle14]BN(6-14), which binds to GRPr with high affinity and specificity, and the peptidomimetic urea-based pseudoirreversible inhibitor of PSMA, Glu-ureido-Lys. The two pharmacophores were coupled through copper(I)-catalyzed azide-alkyne cycloaddition to the bis(tetrafluorophenyl) ester of the chelating agent HBED-CC via amino acid linkers made of positively charged His (H) and negatively charged Glu (E): -(HE)n- (n = 0-3). The BRLs were labeled with 68Ga, and their preliminary pharmacological properties were evaluated in vitro (competitive and time kinetic binding assays) on prostate cancer (PC-3, LNCaP) and rat pancreatic (AR42J) cell lines and in vivo by biodistribution and small animal PET imaging studies in both normal and tumor-bearing mice. The IC50/Ki values determined for all BRLs essentially matched those of the respective monomers. The maximal cellular uptake of the BLRs was observed between 20 and 30 min. The BRLs showed a synergistic ability in vivo by targeting both PSMA (LNCaP) and GRPr (PC-3) positive tumors, whereas the charged -(HE)n- (n = 1-3) linkers significantly reduced the kidney and spleen uptake. The bispecific (PSMA and GRPr) targeting ability and optimized pharmacokinetics of the compounds developed in this study could lead to their future application in clinical practice as more sensitive radiotracers for noninvasive imaging of prostate cancer (PCa) by PET/CT and PET/MRI. 
700 1 |a Schäfer, Martin  |e VerfasserIn  |4 aut 
700 1 |a Haberkorn, Uwe  |d 1959-  |e VerfasserIn  |0 (DE-588)1022913905  |0 (DE-627)717331245  |0 (DE-576)366166352  |4 aut 
700 1 |a Eder, Matthias  |d 1979-  |e VerfasserIn  |0 (DE-588)140263217  |0 (DE-627)616969279  |0 (DE-576)316151092  |4 aut 
700 1 |a Kopka, Klaus  |d 1968-  |e VerfasserIn  |0 (DE-588)173031862  |0 (DE-627)69795661X  |0 (DE-576)133884724  |4 aut 
773 0 8 |i Enthalten in  |t Bioconjugate chemistry  |d Columbus, Ohio : American Chemical Society, 1990  |g 27(2016), 3, Seite 737-751  |h Online-Ressource  |w (DE-627)306655780  |w (DE-600)1500067-9  |w (DE-576)088732371  |x 1520-4812  |7 nnas  |a Novel bispecific PSMA/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer 
773 1 8 |g volume:27  |g year:2016  |g number:3  |g pages:737-751  |g extent:15  |a Novel bispecific PSMA/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer 
856 4 0 |u https://doi.org/10.1021/acs.bioconjchem.5b00687  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200602 
993 |a Article 
994 |a 2016 
998 |g 173031862  |a Kopka, Klaus  |m 173031862:Kopka, Klaus  |p 5  |y j 
998 |g 140263217  |a Eder, Matthias  |m 140263217:Eder, Matthias  |d 50000  |e 50000PE140263217  |k 0/50000/  |p 4 
998 |g 1022913905  |a Haberkorn, Uwe  |m 1022913905:Haberkorn, Uwe  |d 910000  |d 911400  |e 910000PH1022913905  |e 911400PH1022913905  |k 0/910000/  |k 1/910000/911400/  |p 3 
998 |g 1205337059  |a Liolios, Christos  |m 1205337059:Liolios, Christos  |d 50000  |e 50000PL1205337059  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1699161631  |e 368138570X 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedDisp":"January 4, 2016","dateIssuedKey":"2016"}],"relHost":[{"recId":"306655780","name":{"displayForm":["American Chemical Society"]},"origin":[{"dateIssuedDisp":"1990-","publisher":"American Chemical Society","publisherPlace":"Columbus, Ohio","dateIssuedKey":"1990"}],"title":[{"title_sort":"Bioconjugate chemistry","title":"Bioconjugate chemistry"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["1500067-9"],"eki":["306655780"],"issn":["1520-4812"]},"note":["Gesehen am 18.11.08"],"pubHistory":["1.1990 -"],"language":["eng"],"part":{"year":"2016","volume":"27","text":"27(2016), 3, Seite 737-751","extent":"15","pages":"737-751","issue":"3"},"disp":"Novel bispecific PSMA/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancerBioconjugate chemistry","type":{"bibl":"periodical","media":"Online-Ressource"}}],"physDesc":[{"extent":"15 S."}],"id":{"eki":["1699161631"],"doi":["10.1021/acs.bioconjchem.5b00687"]},"title":[{"title_sort":"Novel bispecific PSMA/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer","title":"Novel bispecific PSMA/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 02.06.2020"],"person":[{"given":"Christos","display":"Liolios, Christos","family":"Liolios","role":"aut"},{"family":"Schäfer","role":"aut","display":"Schäfer, Martin","given":"Martin"},{"display":"Haberkorn, Uwe","given":"Uwe","role":"aut","family":"Haberkorn"},{"given":"Matthias","display":"Eder, Matthias","role":"aut","family":"Eder"},{"display":"Kopka, Klaus","given":"Klaus","family":"Kopka","role":"aut"}],"recId":"1699161631","name":{"displayForm":["C. Liolios, M. Schäfer, U. Haberkorn, M. Eder, and K. Kopka"]},"language":["eng"]} 
SRT |a LIOLIOSCHRNOVELBISPE4201